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with HIV Copyright 
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and Anna Turkovaf,gPurpose of review
Adults living with HIV have an increased risk of malignancy yet there is little data for adolescents and young
adults. We reviewed recently published cancer epidemiology, treatment, and outcome data for adolescents
and young adults living with HIV (AYALHIV) aged 10 to less than 25 years between 2016 and 2017.
Recent findings
AYALHIV are at increased risk of developing cancer compared to their uninfected peers. Kaposi sarcoma
and non-Hodgkin lymphoma occur most frequently with variation by geographical region. Increased cancer
risk is associated with HIV-related immunosuppression and coinfection with oncogenic viruses. Published
data, particularly on posttreatment outcomes, remain limited and analyses are hampered by lack of data
disaggregation by age and route of HIV transmission.
Summary
Although data are sparse, the increased cancer risk for AYALHIV is the cause for concern and must be
modified by improving global access and uptake of antiretroviral therapy, human papilloma virus (HPV)
and hepatitis B virus (HBV) vaccination, screening for hepatitis B and C infection, and optimized cancer
screening programs. Education aimed at reducing traditional modifiable cancer risk factors should be
embedded within multidisciplinary services for AYALHIV.
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The number of adolescents and young adults living
with HIV (AYALHIV) continue to rise due to high
rates of new infections and increasing life expec-
tancy on antiretroviral therapy (ART). AYALHIV
(between the ages of 10 to <25 years) account for
13% of those living with HIV; the majority of them
are from sub-Saharan Africa (SSA). Adolescence is
the only age group with a rising AIDS-related mor-
tality [1] (Fig. 1).
Adolescence, transition, and cancer risk
Historically, malignancies in people living with HIV
are categorized as AIDS-defining and non-AIDS-
defining (Table 1) [2,3]. AYALHIV are at increased
risk of developing both AIDS and non-AIDS-defin-
ing cancers compared to HIV-negative individuals
[4]. The increased cancer risk for those living with
HIV is driven by interlinked immunosuppression,
decreased cancer surveillance, persistent coinfection
with oncogenic viruses, and HIV viremia. Immedi-
ate ART initiation, before immunosuppression© 2018 Wolters Kluwer occurs, significantly reduces risk of cancer [5,6
&
].
However, AYALHIV have lower rates of ART uptake,
increased nonadherence to ART, and higher rates of
loss to follow-up compared to younger children
and older adults resulting in poorly controlled
HIV [4,7
&
,8].Health, Inc. All rights reserved.
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KEY POINTS
 AYALHIV are at increased risk of AIDS and non-AIDS
defining malignancies, associated with immune
dysregulation and coinfection with oncogenic viruses.
 Non-Hodgkin lymphoma and Kaposi sarcoma are the
commonest malignancies occurring in
AYALHIV globally.
 Reducing the risk of cancer in AYALHIV requires
increased access to suppressive antiretroviral therapy,
HPV and HBV vaccination, screening and treatment for
HBV/hepatitis C virus coinfection, and programmatic
screening for cervical and anogenital cancers.
 Improvement in cancer estimates for AYALHIV requires
data disaggregated by age and route of HIV
transmission, which is currently lacking.
 Enabling long-term follow-up of children and
adolescents living with HIV, including survivors of a
dual diagnosis of HIV and malignancy as they undergo
transition into adult services, requires effective linkage
of pediatric and adult cohorts.
Table 1. Infection-associated cancers and related clinical
HIV stage
Malignancy
Association with
oncogenic viruses
HIV
staginga
AIDS-defining malignancies
Non-Hodgkin lymphoma
Burkitt’s lymphoma
Large cell (immunoblastic)
lymphoma
Primary central nervous
system lymphoma
EBV
EBV
CDC C
WHO 4
Kaposi sarcoma HHV-8 CDC C, WHO 4
Invasive cervical carcinoma HPV CDC C, WHO 4
Non-AIDS-defining malignanciesb
Smooth muscle tumours
Leiomyoma (benign)
Leiomyosarcoma (malignant)
EBV
EBV
CDC B
Hodgkin lymphoma EBV –
Hepatocellular carcinoma HBV, HCV –
Anal cancer HPV –
aThe Center for Disease Control (CDC) lists NHL, Kaposi sarcoma, and
invasive cervical cancer as Category C (AIDS-defining) illnesses and
leiomyosarcoma as Category B (symptomatic HIV-infection entities not
included in Category C) illnesses [2]. The WHO lists all of these under
Clinical Stage 4 and does not classify leiomyosarcoma [3].
bMany other neoplastic disorders, such as anal cancer, oral squamous
carcinoma, and testicular cancer have been linked to HIV infection and
included in the group of non-AIDS-defining illnesses.
CDC, Center for Disease Control; EBV, Epstein–Barr virus; HBV, hepatitis B
virus; HCV, hepatitis C virus; HHV-8, human herpes virus-8.
Cancer in adolescents and young adults with HIV Bohlius et al.Currently, the most frequent cancers in AYALHIV
are, depending on geographic region, Kaposi sarcoma,
non-Hodgkin lymphoma(NHL),andleiomyosarcoma
[4,9,10,11]. Kaposi sarcoma is associated with human
herpes virus 8 (HHV-8) infection, leiomyosarcoma, Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Estimates for number of adolescents and young adults living with HIV in 2016 stratified by age group, sex, and
UNAIDS region. Estimates for (i) western, central Europe and North America and (ii) eastern Europe and central Asia for
adolescents aged 10 to <15 years are not available. F, female; M, male. Axis Y: Number of adolescents and young adults.
Axis X: UNAIDS regions. Source: UNAIDS 2017 estimates [1].
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Adolescents and HIVand some NHL subtypes, with Epstein–Barr virus
(EBV) infection [12,13]. In American adolescents
(15–19 years) living with HIV, 49% [95% confidence
interval (CI) 39–63] of all cancers were attributable to
infectious precipitants [9]. Higher rates of unprotected
sex in behaviourally infected AYALHIV increase
acquisition of sexually transmitted oncogenic
viruses including high-risk human papilloma viruses
(hrHPVs) and hepatitis B and C viruses (HBV, HCV)
potentiating cervical, oropharyngeal, anogenital can-
cers, and hepatocellular carcinomas (HCCs), respec-
tively [13]. Perinatally infected AYALHIV may face
increased riskof cancer compared to theirbehaviorally
infected peers due to lifelong exposure to HIV,
immune dysregulation, and if coinfected perinatally
with HBV and/or HCV.
Last, the period of transition of healthcare
between pediatric and adult services is associated
with poorer health outcomes in many chronic
diseases, including HIV [14
&&
]. Global models of
transition vary widely between countries, income
settings, and individual diseases and an adolescent
living with HIV and a previous or current cancer
diagnosis may have to negotiate two independent
transition processes [15
&
,16]. For young people liv-
ing with HIV, transition typically occurs during late
teens or early 20s, an age with peak incidence in
Hodgkin lymphoma diagnoses within the general
population [16–18].METHODS
We searched PubMed on November 2nd 2017 (search
terms are shown in Table 2). We restricted the search
to January 1st 2016 to November 1st 2017. We iden-
tified 289 references, which were reviewed by the
authors. We included papers that reported cancer
incidence rates, risk factors, survival, or prevention
interventions in AYALHIV aged 10 to less than 25
years. Papers reporting incidence rate in adults with-
out further age disaggregation for less than 25 year
olds were not considered. We included original
articles, systematic reviews, and case reports. Expert Copyright © 2018 Wolters Kluwer 
Table 2. Search strategy for Medline (PubMed)
((’Neoplasms’[Mesh]) OR (neoplasm[Title/Abstract] OR cancer[Title/Ab
tumor[Title/Abstract] OR malignanc[Title/Abstract] OR leukemi[Title
transplantation[Title/Abstract] OR hematopoietic stem cell transplanta
Abstract] OR hematopoietic cell transplantation[Title/Abstract])) AND (
(adolescen[Title/Abstract] OR juvenil[Title/Abstract] OR youth[Title/
underage[Title/Abstract] OR pubescen[Title/Abstract] OR young adul
HIV[MeSH] OR hiv[tw] OR HIV-1[tw] OR HIV-2[tw] OR HIV1[tw] OR
OR human immunedeficiency virus[tw] OR human immuno-deficiency v
immun) AND (deficiency virus[tw])) OR acquired immunodeficiency sy
acquired immuno-deficiency syndrome[tw] OR acquired immune-deficie
syndrome[tw])) OR ‘sexually transmitted diseases, viral’[MH])
198 www.co-hivandaids.comreviews were excluded. A few older important studies
were used to support key statements.CANCER EPIDEMIOLOGY IN
ADOLESCENTS AND YOUNG ADULTS
LIVING WITH HIV
In the recent literature, there were limited data on
cancers disaggregated by age and virtually no data
disaggregated by mode of HIV transmission. It was,
therefore, not possible to describe differences in
perinatally and horizontally infected AYALHIV.
Although pediatric and adult cohorts linking is being
developed [19,20
&
,21
&
], there are only few longitudi-
nal follow-up results for cancer risk in children and
adolescents transitioning to adult care [22].Non-Hodgkin lymphoma
A single-center cohort study from the United King-
dom reported on the increased risk of a new lym-
phoma diagnoses in young adults living with
perinatally acquired HIV (PaHIV) following transi-
tion to adult care [22]. A total of 5 out of 147 (3.4%)
developed lymphoma at a median (range) age of 19
(18–23) years. Patients presented with advanced
disease (Ann Arbor stage III/IV) mainly diffuse large
B-cell lymphomas, a prolonged history of nonad-
herence, with a life time average of 14 years with
detectable viraemia and a low nadir CD4 cell count
[157 (90–220) cells/ml]. Small numbers precluded
formal risk factor analysis; however, the NHL inci-
dence rate significantly exceeded that of the age
matched general UK population; incidence rate
ratio 25.9 (95% CI 8.31–61.7), P < 0.0001. Treat-
ment outcomes were not reported. This study ech-
oes a previous report from Italy, describing two cases
of Burkitt lymphoma in AYALHIV who were chron-
ically exposed to high-level HIV viremia [23]. These
two case series support the concerns of longer term
oncogenic risk for the current generation of perina-
tally infected AYALHIV who experienced prolonged
viremia due to late diagnosis and have low rates ofHealth, Inc. All rights reserved.
stract] OR carcinoma[Title/Abstract] OR tumor[Title/Abstract] OR
/Abstract] OR leukemi[Title/Abstract] OR hematopoietic stem cell
tion[Title/Abstract] OR hematopoietic cell transplantation[Title/
(’Adolescent’[Mesh]) OR (’Young Adult’[Mesh]) OR
Abstract] OR teen[Title/Abstract] OR underage[Title/Abstract] OR
t[Title/Abstract])) AND (Search HIV Infections[MeSH] OR
HIV2[tw] OR HIV infect[tw] OR human immunodeficiency virus[tw]
irus[tw] OR human immune-deficiency virus[tw] OR ((human
ndrome[tw] OR acquired immunedeficiency syndrome[tw] OR
ncy syndrome[tw] OR ((acquired immun) AND (deficiency
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mens, suboptimal dosing, nonadherence and the
evolution of resistance [22]. Improved HIV diagnosis
and linkage to care, adherence support and potent,
and well-tolerated ART is required to achieve viro-
logical suppression. Greater awareness and prompt
investigation of symptoms is needed to diagnose
NHL at early stages [22].Kaposi sarcoma
We identified one Kaposi sarcoma case series [24
&
]
and two cohort studies reporting incidence rates in
AYALHIV [25,26
&&
]. A cohort study conducted in
Uganda and Kenya reported crude Kaposi sarcoma
incidence rates for AYALHIV (18–24 years) higher in
ART nonusers than in ART users [13]. Incidence rates
tended to be higher in young men than in
women;[25] although, it is unclear whether this is
explained by higher prevalence of HHV-8 [27],
delayed access, and poorer adherence to ART in
young men or additional factors. Another study from
Malawi reported a steady increase in Kaposi sarcoma
cases in adolescents per annum despite improved
ART coverage [24
&
]. The average annual number of
Kaposi sarcoma diagnoses in children and adoles-
cents from 2006 to 2010 (n¼89) was 17.8 cases per
year, compared to 25.2 cases per year from 2011 to
2015 (n¼126) [24&]. This may be explained by better
Kaposi sarcoma diagnosis with the improved HIV
care [24
&
]. A third study reported Kaposi sarcoma
incidence rates for AYALHIV (aged 16–24 years) from
Europe, South Africa,NorthAmerica, andAsia. In this
multiregional cohort analysis adolescents in South
Africa had very high Kaposi sarcoma incidence rates
(303, 95% CI 176–523) per 100 000 person years,
followed by adolescents in Latin America, North
America, and Europe (Table 3).Invasive cervical cancer
Cervical cancer is the fourth leading cause of cancer
incidence and mortality for women globally [28,29].
In AYALHIV, one cohort study reported an incidence Copyright © 2018 Wolters Kluwe
Table 3. Kaposi sarcoma incidence rate in HIV-positive adolesce
Study Country/region Age gro
Semeere et al. [25] Uganda, Kenya 18
Uganda, Kenya 20
Rohner et al. [30&&] South Africa 16
Latin America 16
North America 16
Europe 16
CI, confidence interval.
1746-630X Copyright  2018 Wolters Kluwer Health, Inc. All rights reserate for invasive cervical cancer (ICC) in young
women (18–25 years) of 223 (100–496) per 100 000
person years [30
&&
]. Women living with HIV have
higher hrHPV prevalence [31,32] and more diverse
HPV subtypes than their HIV negative counterparts
[33,34
&
,32]. HIV-infected young women have high
incidence of cervicaldysplasia [35]; compared to HIV-
uninfected peers, the rate has been with reported
incidence to be three times higher [36].Hepatocellular carcinoma
HIV/HBV and HIV/HCV coinfections are associated
with an increased risk of liver disease including HCC
in adults; however, there are minimal data in those
coinfected either perinatally or in childhood [37
&
].
Two cases of HCC in adolescents are described in the
literature. One male, of black African origin, with
PaHIV/HBV developed a rapidly progressive HCC
aged 19 despite more than a decade of suppressive
ART for both HBV and HIV and regular HCC screen-
ing. Despite timely surgery, he died of recurrent
metastatic HCC within a year of diagnosis [37
&
]. A
second adolescent with PaHIV developed an HCC
but with no evidence of hepatitis coinfection. He
had slow disease progression despite being severely
immunocompromised, with no evidence of recur-
rence more than a year from surgical resection [38].Smooth muscle tumours
A recent study from South Africa reported a case
series of EBV-associated smooth muscle tumors in
AYALHIV and adults [39]. Five cases occurred in
adolescents (10–15 years) with median CD4 cell
count 616 (range 1–1331) cells/ml; all were female,
and all but one survived [39].TREATMENT, PROGNOSIS, AND
SURVIVORSHIP
There were limited published data for cancer out-
comes in AYALHIV; however, adult studies suggestr Health, Inc. All rights reserved.
nts and young adults who started antiretroviral therapy.
up [years] Rate (95% CI) per 100,000 person-years
–19 245 (79–760)
–24 323 (245–426)
–25 303 (176–523)
–25 248 (141–438)
–25 95 (36–253)
–25 115 (93–143)
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Adolescents and HIVdisparities in access to cancer treatment and poorer
outcomes in adults living with HIV compared to
their uninfected peers [40
&
]. A retrospective obser-
vational study from Malawi reported treatment out-
comes for 70 children and adolescents with HIV
(median age 8.6 (1.7–17.9) years) diagnosed with
Kaposi sarcoma [41]. Local first-line chemotherapy
included bleomycin and vincristine (BV). In 2012,
doxorubicin became available in Malawi, which was
added for second-line therapy. Paclitaxel was used
for the third line. ART-naı¨ve individuals started
nevirapine-based ART within 2 weeks of chemother-
apy. Of all patients, 28% had severe immunosup-
pression and nearly half were on ART at time of
Kaposi sarcoma diagnosis. The combination of BV
was well tolerated with ART, with minimal severe
adverse events. Over half (58%) have survived at
median follow-up of 29 (15–50) months. Lympha-
denopathic Kaposi sarcoma, the most common clin-
ical presentation in children in eastern Africa, was
associated with the best outcomes. Kaposi sarcoma
with woody edema had a more chronic disease
course, whereas visceral disease and Kaposi sarcoma
with more than 20 widespread ‘disseminated’ skin/
oral lesions were independently associated with
increased mortality. Identifying risk factors associ-
ated with unfavorable outcomes may be critical to
determining which patients will require alternative
therapeutic strategies [41].
Timely ART initiation in individuals with HIV-
related malignancies reduces morbidity associated
with opportunistic infections and improves overall
survival. However, preexisting HIV-associated organ
dysfunction, coexistence of opportunistic infections,
compound immunosuppression caused by HIV and
chemotherapy, as well as drug interactions between
ART and chemotherapy and overlapping treatment-
related toxicities make management of patients with
HIV and cancer complex. A recent study suggests
coadministration of chemotherapy with ART based
on integrase strand-transfer inhibitors or nonnucleo-
side reverse transcriptase inhibitors but not boosted
protease inhibitors results in better safety profiles and
higher suppressed viral replication [39].
Adult survivors of childhood/adolescent cancer
have a lifelong increased morbidity and mortality as
well as amplified risk of secondary malignancy [42].
Morbidity may be multisystem impacting on cardio-
respiratory, skeletal, renal, neurocognitive, endocrine,
and reproductive health compounded with signifi-
cant psychosocial issues affecting mental health
[43
&
]. Annual reviews are recommended for survivors
of childhood cancer for screening, prevention, and
treatment of late effects; however, uptake following
transition to adult care is poor [44]. AYALHIV who
survived malignancy face similar issues compounded Copyright © 2018 Wolters Kluwer 
200 www.co-hivandaids.comby risk of cumulative long-term sequelea of HIV.
Potentially, they have an increased risk of a secondary
malignancy due to their underlying immune dysre-
gulation and require enhanced support during transi-
tion to ensure retention in care and viral suppression.PRIMARY AND SECONDARY PREVENTION
Early HIV diagnosis and timely ART may substan-
tially reduce the risk of AIDS-defining cancers
[5,6
&
,10,11,45
&
]. Unlike for HPV, HBV, and HCV,
there are no vaccines or specific treatment for EBV
and HHV-8, and early access to suppressive ART
remains the most important preventive measure
for cancers related to these infections.High-risk variants of human papilloma virus
The high global prevalence of persistent hrHPV
infection in both female and male AYALHIV
[33,34
&
,46,47,35] and high proportion of high-grade
precancerous lesions [35] highlight the importance
of sex-neutral HPV vaccination. HPV vaccination
induces good HPV-specific cell-mediated immune
responses in AYALHIV, compared to HIV-unin-
fected age-matched controls; although, three rather
than two doses are still recommended for AYALHIV
due to a data gap [48]. Currently, only 11 (6%)
countries vaccinate males in their national immu-
nization programs [49
&&
]. WHO and American Soci-
ety of Clinical Oncology (ASCO) guidance prioritize
vaccination of girls based on cost-effectiveness anal-
yses for prevention of cervical cancer; boys can be
included if the vaccine uptake among priority
female population is less than 50% and resources
are available [49
&&
,50
&&
]. A relatively high proportion
of hrHPV types in young women in SSA are not
covered by currently available HPV vaccines,
[31,51] which supports early initiation of cervical
screening for all sexually active women living with
HIV irrespective of age as recommended by WHO
and ASCO [49
&&
,52
&&
]. A study from Saudi Arabia
showed that male circumcision may play role in
reduction of HPV infection, penile cancers, and
cervical cancer among women with circumcised
partners [53]. Screening for anal cancers is not rou-
tinely recommended; although, some experts sug-
gest that this might be effective [54
&
,55]. There is an
urgent need of prospective studies validating differ-
ent approaches for prevention and screening of
cervical and anogenital cancers.Hepatitis B and C
Occurrence of HCC early in adulthood underlines
the importance of primary prevention with HBVHealth, Inc. All rights reserved.
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HCV coinfection. Systematic screening for HBV
and HCV infection is limited in most sub-Saharan
African countries [56
&
]. Hepatitis B vaccination from
birth with serological monitoring and boosting
when appropriate, and education around preven-
tion of HCV acquisition should be embedded within
the life span care of those living with HIV. There is
no consensus on HCC screening; although, 6
monthly liver ultrasounds and alpha-fetoprotein
are supported by WHO guidance [38,57]. Reducing
risk of HCC includes HBV viral suppression with
tenofovir-based regimens, avoidance of excessive
alcohol and weight optimization. Increased advo-
cacy for rapid access to curative direct-acting anti-
virals for HCV for coinfected adolescents is
urgently required.
Knowledge, awareness, and uptake of sexual and
reproductive health services (SRS) is insufficient
among young people [58,59]. Enhanced counsel-
ling, integration, or linkage to SRS can improve
the uptake of voluntary male circumcision and cer-
vical cancer screening [60]. AYALHIV require access
to ‘youth friendly’ SRS integrated within multidis-
ciplinary HIV care that includes primary prevention
packages addressing vaccination, ART adherence,
smoking [33], alcohol and substance use [61],
weight management, and where appropriate screen-
ing for HPV, HBV, and HCV-related malignancies.CONCLUSION
People living with HIV, including adolescents and
young adults, are at increased risk of malignancy,
due to immune dysregulation and the persistence of
oncogenic viruses. While the excess cancer risk is
reduced with suppressive ART, ART coverage is still
suboptimal in many settings, and AYALHIV have
the lowest rates of engagement with each aspect of
the HIV care cascade. Improving HIV diagnosis,
linkage, and retention in care on sustained suppres-
sive ART for AYALHIV remains the most important
cancer preventive measure. However, this must go
hand in hand with integrated cancer screening and
education programs including prevention of tradi-
tional cancer modifiable risk factors for a vulnerable
population who currently face an increased life time
risk of malignancy, while they negotiate their tran-
sition to adulthood living with HIV. Increased
awareness among healthcare workers and prompt
investigation of suggestive symptoms is needed to
diagnose cancers at early stages. In the era of effec-
tive ART, AYALHIV should have access to cancer
treatment and supportive care compared to their
uninfected peers. Copyright © 2018 Wolters Kluwe
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